India's Biocon has expanded its pipeline of biosimilars with a $3.3 billion deal to acquire a portfolio of drugs from Viatris, the parent of its longstanding partner Mylan, which will boost its ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

However, the company also announced at the same time that it was selling its biosimilars portfolio to Biocon for $3.3 billion, amid a commercial environment where even brand products were seeing ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Biocon Biologics partners with Civica Inc to increase affordability and access to Insulin Aspart in the US, targeting the 38.4 million Americans with diabetes. Mar 06, 2025 19:03 Biocon Launches ...

SBI Multi Asset Allocation Fund (G) 61.92 19,16,589 0.84 SBI Multi Asset Allocation Fund (IDCW-M) 61.92 19,16,589 0.84 SBI Multi Asset Allocation Fund (IDCW-Q) 61.92 ...

Biocon Biologics India Limited is an Indian Non-Government Company. It's a public company and is classified as'company limited by shares'. Company's authorized capital stands at Rs 5.0 lakhs and has ...

At close: March 21 at 3:29:57 PM GMT+5:30 ...

Civica will start selling the medicine for patients in the United States after completing development work and clinical trials.

Competition page helps you compare Biocon Ltd. with its sector peers on key parameters.